Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Chief Accounting Officer | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,586 |
Ending reported balance
After 2026-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 563 · Balance 1,797 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-02-23 · Sale · Disposed 211 · Balance 1,586 F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,689 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Exercise / conversion · Disposed 563 · Balance 1,689 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2024 Filed Feb 13, 2024 02:46 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 5,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-24-000587 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 108 | $1.23 | $132.36 |
DisclosureSEC source: 0000905148-23-001385 · form4.xml · nonDerivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,251 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 107 | $1.27 | $135.96 |
DisclosureSEC source: 0000905148-23-001385 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,359 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 601 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-001385 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,415 Underlying: Common Stock · 601 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 21:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-23-001385 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 23:30 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 279 | $1.27 | $353.47 |
DisclosureSEC source: 0000905148-23-000668 · form4.xml · nonDerivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,865 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 23:30 UTC | BIODESIX INC BDSX · Entity 6053 | SaleCommon Stock | 280 | $1.39 | $388.72 |
DisclosureSEC source: 0000905148-23-000668 · form4.xml · nonDerivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,144 F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:30 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 814 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-000668 · form4.xml · derivative · entry 5 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:30 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionRestricted Stock Units · Derivative | 603 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-23-000668 · form4.xml · derivative · entry 4 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,016 Underlying: Common Stock · 603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 23:30 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 1,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-23-000668 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:34 UTC | BIODESIX INC BDSX · Entity 6053 | GrantCommon Stock | 617 | $1.62 | $999.54 |
DisclosureSEC source: 0000905148-23-000629 · form4.xml · nonDerivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,007 Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:18 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 25,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000905148-23-000513 · form4.xml · derivative · entry 3 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-07-23 F5 · derivative.exercise_date: This option vests in a series of 48 successive, equal monthly installments measured from July 24, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:18 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 3,266 | Not disclosed Strike: $1.20 | Not disclosed |
DisclosureSEC source: 0000905148-23-000513 · form4.xml · derivative · entry 2 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,266 Underlying: Common Stock · 3,266 shares Expires 2033-07-23 F2 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F3 · kind: The Reporting Person elected to participate in the Tender Offer and received 3,266 Replacement Options with an exercise price of $1.20 per share in exchange for 16,000 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F2 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F3 · price: The Reporting Person elected to participate in the Tender Offer and received 3,266 Replacement Options with an exercise price of $1.20 per share in exchange for 16,000 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F4 · derivative.exercise_date: This Replacement Option vests as follows: 1,579 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 1,687 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:18 UTC | BIODESIX INC BDSX · Entity 6053 | Disposition to issuerStock Options (Right to buy) · Derivative | 16,000 | Not disclosed Strike: $20.67 | Not disclosed |
DisclosureSEC source: 0000905148-23-000513 · form4.xml · derivative · entry 1 Vazquez Chris · CIK 0001980594 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2031-02-22 F2 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F3 · kind: The Reporting Person elected to participate in the Tender Offer and received 3,266 Replacement Options with an exercise price of $1.20 per share in exchange for 16,000 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F2 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. F3 · price: The Reporting Person elected to participate in the Tender Offer and received 3,266 Replacement Options with an exercise price of $1.20 per share in exchange for 16,000 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. F1 · derivative.exercise_date: This option vested 40% on February 23, 2023, and the remaining 60% were scheduled to vest in 36 successive, equal monthly installments measured from February 23, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.